Kenneth Galbraith
Kenneth Galbraith is the CEO of Zymeworks Inc., a Vancouver-based biotechnology company specializing in cancer treatments. He took the helm following the departure of co-founder Ali Tehrani and has been instrumental in steering the company towards success, particularly with the lead drug Ziihera, which has shown promising results in clinical trials for digestive system cancers. Under his leadership, Zymeworks has secured a partnership with Jazz Pharmaceuticals to commercialize Ziihera, significantly improving investor confidence and the company’s stock performance.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 2 | 8.00 | 0.17% | +10% | 38,005,238 | 69,968 | $1,700,000 | 3,130$ |
| Totals | 2 | 38,005,238 | 69,968 | $1,700,000 | 3,130$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Kenneth Galbraith is the CEO of Zymeworks and has unveiled a new strategy for the company.
7
Canada:
Zymeworks CEO Kenneth Galbraith said in a release that the results represent a true turning point for patients with GEA.
9